Anti-alpha 5 beta 1 Integrin [M200 (Volociximab)]

Absolute Antibody

Anti-alpha 5 beta 1 Integrin [M200 (Volociximab)]

9

The antibody binds to human alpha5beta1 integrin with a Kd of 0.367 nM (determined by Biacore), an EC50 of 0.2 nM and an IC50 of 2.3 nM.

The antibody binds specifically to alpha5beta1 integrin, which is part of the superfamily of glycoprotein transmembrane receptors for ligands such as fibronectin, vitronectin, laminins and collagens. The alpha5beta1 integrin receptor plays a key role in cellular processes such as inflammation, cell proliferation, angiogenesis and tumour metastasis. Comprising the variable domain of the original mouse antibody, a chimeric mouse:human IgG4 version of this antibody has been tested in vivo: In cynomolgus monkeys with laser-induced choroidal neovascularization (CNV), in rabbit models and in human volunteers. The antibody reached Phase II clinical trials with PDL Biopharma and Biogen-Idec.

Flow Cytometry, ImmunoFluorescence, ELISA, ImmunoHistoChemistry, Neutralisation/Blocking

Research Use Only

Monoclonal

M200 (Volociximab)

ITGA5

integrin subunit alpha 5

CD49 antigen-like family member E; CD49e; fibronectin receptor subunit alpha; fibronectin receptor, alpha polypeptide; fibronectin receptor, alpha subunit; FNRA; integrin alpha-5; integrin alpha-F; integrin, alpha 5 (fibronectin receptor, alpha polypeptide); ITGA5/SLC9B1 fusion; very late activation protein 5, alpha subunit; VLA-5; VLA5A

Mouse

IgG1

Integrin alpha-5

NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques.

Human

-20°C,2°C to 8°C

12352203